Informations sur le produit
- (3aR-trans)-5-Chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole 2-oxide
Asenapine N-oxide is a non-competitive antagonist of dopamine D2 and serotonin 5HT2a receptors. It belongs to the atypical antipsychotics, which are used in the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Asenapine N-oxide has been shown to have a pharmacokinetic profile that is not compartmentalized, unlike most other drugs. This means that asenapine N-oxide does not accumulate in any specific tissue or organ when it is taken orally, but instead distributes evenly throughout the body. This helps to minimize unwanted side effects such as weight gain or extrapyramidal symptoms. Clinical studies have shown that there are no clinically significant pharmacokinetic interactions with healthy controls and those on other medications like clozapine or risperidone. Monitoring parameters for patients taking asenapine N-oxide include clinical response, body mass index (BMI), and hepatic impairment.
